A Medical Device Daily

Arteriocyte (Cleveland) reported receiving a Small Business Technology Transfer (STTR) grant of $1.4 million to fund its Phase I trial to evaluate the safety of adult derived hemangioblasts (stem cells) to treat chronic ischemia. The company said that the first patient to enroll in the trial was treated at University Hospitals of Cleveland.

Arteriocyte said that the clinical study is one of the first in the U.S. to evaluate the safety of delivering adult-derived stem cells through a catheter into the coronary arteries of patients suffering from a condition in which one or more of the primary arteries supplying blood flow to the heart are clogged. The method was developed by Mary Laughlin, MD, a hematologist, and Vincent Pompili, MD, a cardiologist, of Case Western Reserve University (Cleveland) and University Hospitals of Cleveland.

The study will enroll 10 patients who are not candidates for existing treatments such as angioplasty or stent placement.

“Traditionally, physicians have been able to prevent heart attack or alleviate its after-effects, but they have not figured out how to initiate the sort of blood vessel repair that remains a key to survival,“ said Laughlin. “Now there is promise of achieving that repair by infusing highly selected marrow stem cells.“

Arteriocyte, an early-stage biotech firm developed out of NIH-sponsored research utilizing stem cells to stimulate angiogenesis, says its ultimate goal is to develop umbilical cord blood as the basis for cellular medicines.

In other grant/contract news:

The University of Texas Southwestern Medical Center at Dallas has selected the Premier (San Diego) alliance of more than 1,400 not-for-profit hospitals as its group purchasing and supply chain services partner.

Formerly a member of GPO Novation (Irving, Texas), UT Southwestern joins more than 200 of the nation's hospital and healthcare systems who own Premier.

Premier will provide UT Southwestern group contracts including national, regional, and local contracting options as well as support from the Premier regional team, supply chain automation tools and access to supply chain benchmarking and performance improvement resources.

John Johnston, Premier region vice president for Premier, said, “UT Southwestern Medical Center adds to Premier's strong position in the fast-growing Dallas-Fort Worth market. More important, we are now partners with one of the leading research and patient care centers.“

Hatch Medical (Duluth, Georgia), a medical device incubator and technology brokerage firm, reported entering into an agreement with Australian physician inventor and interventional radiologist, John Coucher, MD, to broker his patent-pending Co-axial Biopsy System Adaptor. Hatch said that Coucher's “simple and inexpensive device“ allows for adjustable and precise biopsy needle excursions without using an “adjustable-firing-depth“ biopsy device, the company said.

This technology is available to be licensed or acquired by interested third parties through an agreement with Hatch.

HemoBioTech (Dallas) reported that it has signed a third-stage-sponsored research agreement (SRA) with the Texas Tech University Health Sciences Center (TTUHSC; Lubbock). The SRA will focus on the manufacture of clinical grade HemoTech, the company's product that it describes as an “oxygen-carrying solution that performs like red blood cells.“

The third-stage SRA follows a second-stage SRA between HemoBioTech and TTUHSC that was completed in December.

No Comments